Market Overview

UPDATE: Ladenburg Thalmann Maintains Buy Rating, Raises PT for Optimer Pharmaceuticals

Related OPTR
HSR Waiting Period Expires for Cubist, Optimer Deal
Cubist Pharma Reports Pricing of $700M in Convertible Senior Notes, Expecting Proceeds of $679M

In a company update published earlier today, Ladenburg Thalmann Financial Services maintained its Buy rating for Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and raised its price target from $15.00 to $17.00.

Ladenburg Thalmann said in its report “We believe Dificid [trade name for the antibiotic Fidaxomicin] commercial launch is going as we expected and is on track to reaching the sales milestones set with Cubists [Cubist Pharmaceuticals, Inc.]. In addition, in spite its high price, the medical need in the refractory/recurrence patient population appears to be large enough to maintain revenue growth before Dificid is positioned as a potential first line therapy in high risk populations. We believe success in high risk patient populations is necessary for the long term success of the drug (we believe it is too early to evaluate whether or not this is likely to be the case).”

Optimer Pharmaceuticals, Inc. closed yesterday at $14.80.

Latest Ratings for OPTR

Jul 2013JefferiesDowngradesBuyHold
Jul 2013Canaccord GenuityDowngradesBuyHold
May 2013BairdDowngradesOutperformNeutral

View More Analyst Ratings for OPTR
View the Latest Analyst Ratings

Posted-In: Ladenburg Thalmann Financial ServicesAnalyst Color Price Target Reiteration Analyst Ratings


Related Articles (OPTR)

View Comments and Join the Discussion!

Partner Center